IV medicine to quickly reverse severe cannabis intoxication and stop cannabis-related vomiting
Development of an intravenous CB1 antagonist for acute cannabinoid intoxication and cannabis hyperemesis syndrome
A fast-acting IV medicine that blocks the brain's cannabis receptor to help people with dangerous cannabis overdoses or repeated severe vomiting from cannabis.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Anebulo Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Lakeway, United States) |
| Project ID | NIH-11139389 on NIH RePORTER |
What this research studies
This project is developing an intravenous CB1 antagonist — a medicine that blocks the main brain receptor THC uses — so it can be given quickly when cannabis causes severe symptoms. Researchers plan laboratory and preclinical testing and steps toward use in hospital emergency departments so the drug can be administered right away. The aim is a short-acting treatment you could receive when THC causes panic, psychosis, very fast heart rate, or prolonged nausea and vomiting. If it proves safe, future testing would involve patients who come to EDs with acute cannabinoid intoxication or cannabinoid hyperemesis syndrome.
Who could benefit from this research
Good fit: People who present to an emergency department with severe cannabis intoxication or ongoing, severe vomiting believed to be cannabinoid hyperemesis would be the main candidates.
Not a fit: People with mild, short-lived cannabis effects, symptoms caused by other conditions, or those with contraindications to CB1-targeting drugs are unlikely to benefit.
Why it matters
Potential benefit: Could quickly relieve dangerous cannabis effects and stop prolonged vomiting, reducing emergency visits and hospital stays.
How similar studies have performed: Blocking CB1 has shown promise in animal studies and is a logical way to reverse THC effects, but prior oral CB1 blockers caused psychiatric side effects with long-term use and IV reversal for acute toxicity has limited human experience.
Where this research is happening
Lakeway, United States
- Anebulo Pharmaceuticals, INC. — Lakeway, United States (Active)
Researchers
- Principal investigator: Cundy, Kenneth — Anebulo Pharmaceuticals, INC.
- Study coordinator: Cundy, Kenneth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.